Key clinical point: Erenumab demonstrated a more favorable efficacy profile than rimegepant for the prevention of episodic and chronic migraine.
Major finding: Compared with 75 mg rimegepant, 70 mg erenumab significantly reduced monthly migraine days (MMD) by 0.90 days at 3 months (P = .042) and 140 mg erenumab significantly reduced MMD by 0.94 (P = .014) and 1.28 (P = .005) days at 1 month and 3 months, respectively. Erenumab showed advantages over rimegepant in improving Migraine-Specific Quality-of-life role function-restrictive domain and Migraine Disability Assessment scores (MIDAS) at 3 months.
Study details: This study performed anchored matching-adjusted indirect comparison of the relative efficacy of two erenumab regimens (70 mg and 140 mg) with rimegepant (75 mg) for migraine prevention using data from two phase 2/3 trials for erenumab (295 and STRIVE) and a phase 2/3 trial for rimegepant.
Disclosures: This study was funded by Novartis Healthcare Pvt. Ltd. Several authors declared being employees of and holding stocks or stock options in Novartis.
Source: Mahon R et al. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison. J Comp Eff Res. 2024 (Jan 4). doi: 10.57264/cer-2023-0122